2. Signaling Pathways
  3. Anti-infection
  4. Enterovirus

Enterovirus

Rhinovirus; HRV; HRVs; HEV; HEVs

Enterovirus

Related Products

PDF 0.17 MB

The genus Enterovirus (EV) belonging to the Picornaviridae family comprises 13 species, of which seven are human viruses. Four of the species are: (1) EV-A such as coxsackievirus (CV)-A6, CV-A10, CV-A16 and EV-A71, (2) EV-B such as the CV-B viruses, echoviruses (ECHO) and CV-A9, (3) EV-C such as polioviruses (PV) and CV-A21, (4) EV-D such as EV-D68 and EV-D70. The other three species are rhinoviruses RV-A, RV-B and RV-C which comprised over 100 different numbered RVs. Infection with enteroviruses can cause numerous clinical conditions including poliomyelitis, meningitis and encephalitis, hand-foot-and-mouth disease, acute flaccid paralysis, diarrhea, myocarditis and respiratory illness.

Enteroviruses are small, nonenveloped, positive-sense, single-stranded RNA viruses with an icosahedral capsid. The genome of ∼7.5 kb encodes a single polyprotein that is autoprocessed into structural proteins (VP1, VP2, VP3, and VP4), nonstructural proteins (2A, 2B, 2C, 3A, 3B, 3C, and 3D), and several functional processing intermediates. The viral nonstructural proteins, particularly the protease 3Cpro and the RNA-dependent RNA polymerase 3Dpol, are attractive targets for antiviral drug development.

Enterovirus Related Products (141):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-179469
    KR-27452
    		Inhibitor
    KR-27452 is a selective and orally active PI4KIIIβ inhibitor with an IC50 of 0.026 μM, while showing no activity against PI4KIIIα (IC50 >10 μM) . KR-27452 specifically binds to and inhibits PI4KIIIβ, leading to reduced viral replication in cells. KR-27452 exhibits strong antiviral activity against human rhinovirus (RVs) and Coxsackievirus (COXs). KR-27452 can be used for the research of infection.
    KR-27452
  • HY-172216
    EV-A71-IN-3
    		Inhibitor
    EV-A71-IN-3 (Compound IRE-03-3) is the inhibitor for Enterovirus A71 EV-A71 that targets internal ribosomal entry site (IRES) of EV-A71, inhibits IRES-mediated translation, and inhibits the viral proliferation with an EC50 of 11.96 μM.
    EV-A71-IN-3
  • HY-101064S4
    Fmoc-leucine-15N
    		Inhibitor 98.5%
    Fmoc-leucine-15N is a 15N-labeled and 15N-labled Fmoc-leucine (HY-101064).
    Fmoc-leucine-<sup>15</sup>N
  • HY-174815
    Jun15799
    		Inhibitor
    Jun15799 is an Enterovirus (EVs) 2C protein (EVs 2C) inhibitor with Kis of 0.8, 21.1 and 3.0 μM for EV-D68, EV-A71 and CVB3, respectively. Jun15799 has a significant antiviral activity against EV-D68 US/MO/14-18947, EV-A71 Tainan/4643/1998 and CVB3 Nancy cells (EC50s of 0.3, 11.4 and 0.3 μM, respectively). Jun15799 can be used for viral infections research, such as meningitis, hand, foot and mouth disease (HFMD) and viral myocarditis.
    Jun15799
  • HY-186075
    PS1097
    		Inhibitor
    PS1097 is a broad-spectrum antiviral inhibitor with a BVDV RdRp IC50 of 0.64 μM. PS1097 selectively reduces RTN3 protein levels, causes partial RTN3 mRNA reduction, and leaves other endoplasmic reticulum-resident proteins unaffected. PS1097 inhibits replication of Zika virus and multiple viruses that use the endoplasmic reticulum as a replication hub. PS1097 inhibits BVDV RdRp enzymatic activity and exerts activity against Bovine Viral Diarrhea Virus. PS1097 can be used for the research of zika virus infection, usutu virus infection, west nile virus infection, COVID-19, coxsackie b virus 5 infection, chikungunya virus infection, vaccinia virus infection.
    PS1097
  • HY-D0205AR
    Carbocisteine (Standard)
    		Inhibitor
    Carbocisteine (Standard) is the analytical standard of Carbocisteine. This product is intended for research and analytical applications. Carbocisteine, a mucolytic agent, can be used for the research of chronic obstructive pulmonary disease (COPD).
    Carbocisteine (Standard)
  • HY-B1030R
    Lanatoside C (Standard)
    		Inhibitor
    Lanatoside C (Standard) is the analytical standard of Lanatoside C. This product is intended for research and analytical applications. Lanatoside C is a cardiac glycoside, can be used in the treatment of congestive heart failure and cardiac arrhythmia.Lanatoside C has an IC50 of 0.19 μM for dengue virus infection in HuH-7 cells. Lanatoside C can effectively inhibit all four serotypes of dengue virus, flavivirus Kunjin, alphavirus Chikungunya, Sindbis virus and the human enterovirus 71.
    Lanatoside C (Standard)
  • HY-B1693R
    Levomepromazine (Standard)
    		Inhibitor
    Levomepromazine (Standard) is the analytical standard of Levomepromazine. This product is intended for research and analytical applications. Levomepromazine (Methotrimeprazine) is an orally active antipsychotic compound and Ca2+ release inducer. Levomepromazine inhibits SERCA pump and induces an increase in cytoplasmic Ca2+ levels. Levomepromazine has antagonistic effects on a variety of neurotransmitter receptors, including dopamine, cholinergic, serotonin, and histamine receptors. Levomepromazine can induce adaptive ER stress and autophagy. In addition, Levomepromazine has antiviral, anti-inflammatory, neuroprotective and analgesic, sedative and anti-injurious activities. Levomepromazine can be used in the study psychiatric disorders and relieving nausea and vomiting.
    Levomepromazine (Standard)
  • HY-W012017R
    2-Hydroxytetradecanoic acid (Standard)
    		Inhibitor
    2-Hydroxytetradecanoic acid is a hydroxy fatty acid that inhibits cleavage between the enterovirus capsid proteins VP4 and VP2. 2-Hydroxytetradecanoic Acid has anti-virus activity.
    2-Hydroxytetradecanoic acid (Standard)
  • HY-106774
    R-61837
    		Inhibitor
    R-61837 is a synthetic antirhinoviral compound with significant in vitro activity. R-61837 is 10 times and 57 times more active against human rhinovirus type 9 (HRV-9) than Enviroxime and dichloroflavone (DCF), respectively, and is more active against human rhinovirus type 2 (HRV-2 ) were 5 times and 10 times higher respectively.
    R-61837
  • HY-104074R
    Pocapavir (Standard)
    		Inhibitor
    Pocapavir (Standard) is the analytical standard of Pocapavir (HY-104074). This product is intended for research and analytical applications. Pocapavir (SCH-48973) is an orally active capsid inhibitor. Pocapavir prevents virion uncoating upon entry into the cell. Pocapavir has antiviral activity against polioviruses. Pocapavir also inhibits enterovirus infections.
    Pocapavir (Standard)
  • HY-175165
    Jun6504
    		Inhibitor
    Jun6504 is an enterovirus 2C inhibitor. Jun6504 shows potent and broad-spectrum antiviral activity against multiple strains of EV-D68 (EC50 = 250 nM), EV-A71 (EC50 = 502.4 nM), and CVB3 (EC50 = 1049 nM). Jun6504 improves paralysis score and weight gain in a neonatal mouse model of EV-D68 infection. Jun6504 reduces viral titers in the spinal cord and the infected quadriceps muscle. Jun6504 can be used for EV-D68 antiviral research.
    Jun6504
  • HY-175740
    Antiviral agent 71
    		Inhibitor
    Antiviral agent 71 (Compound 26) is an antiviral agent. Antiviral agent 71 has a broad-spectrum enterovirus antiviral activity, such as EV-D68, Echo-11 and HRV-14 with EC50s of 0.017-4.1 μM. EV-D68-IN-1 can be used for non-polio enteroviruses (NPEV) infections research.
    Antiviral agent 71
  • HY-N7108R
    7-Hydroxyflavone (Standard)
    		Inhibitor
    7-Hydroxyflavone (Standard) is the analytical standard of 7-Hydroxyflavone. This product is intended for research and analytical applications. 7-Hydroxyflavone is a flavonoid isolated from Clerodendrum phlomidis, with anti-inflammatory activity. 7-Hydroxyflavone protects renal cells from nicotine (NIC)-associated cytotoxicity via the ERK/Nrf2/HO-1 pathway. 7-Hydroxyflavone inhibits PKM2 with an IC50 of 2.12 μM. 7-Hydroxyflavone inhibits COX-2 and 5-LOX with IC50 of 27 µg/mL and 33 µg/mL. 7-Hydroxyflavone is orally active.
    7-Hydroxyflavone (Standard)
  • HY-153517
    hRVs-IN-1
    		Inhibitor
    hRVs-IN-1 (Compound 6g) is a selective anti-hRV viral agent. hRVs-IN-1 inhibits the replication of tested hRV strains with EC50 values of 0.083, 0.078, and 0.015 μM against hRV-B14, hRV-A21, and hRV-A71, respectively. hRVs-IN-1 inhibits the replication of PV3 with an EC50 of 0.063 μM.
    hRVs-IN-1
  • HY-175557
    PI4K-IN-2
    		Inhibitor
    PI4K-IN-2 (Compound 30) is a highly selective type III phosphatidylinositol 4-kinase β (PI4KB) inhibitor (IC50=0.015 μM). PI4K-IN-2 is promising for research of human rhinovirus (HRV).
    PI4K-IN-2
  • HY-100679S
    Pirlindole-d4
    Pirlindole-d4 is the deuterium labeled Pirlindole.
    Pirlindole-d<sub>4</sub>
  • HY-100679R
    Pirlindole (Standard)
    		Inhibitor
    Pirlindole (Standard) is the analytical standard of Pirlindole. This product is intended for research and analytical applications. Pirlindole is a selective and reversible MAO-A inhibitor. Pirlindole is also an inhibitor of enterovirus-D68 and coxsackievirus B3 (CV-B3).
    Pirlindole (Standard)
  • HY-106161S1
    Rupintrivir-d7
    		Inhibitor
    Rupintrivir-d7 is a deuterated labeled Rupintrivir. Rupintrivirvr (AG7088), an antiviral agent, is a potent, selective and irreversible inhibitor of human rhinovirus (HRV) 3C protease. Rupintrivirvr inhibits replication of a panel of 48 different HRV serotypes in H1-HeLA and MRC-5 cell protection assays, with a mean EC50 of 0.023 μM. Rupintrivirvr shows immune-modulatory effect.
    Rupintrivir-d<sub>7</sub>
  • HY-N14780
    Pochonin D
    		Inhibitor
    Pochonin D ((+)-Pochonin D) is an inhibitor of heat shock protein 90 (Hsp90) with antiviral and anti-inflammatory activities. Pochonin D inhibits Hsp90, affects the homeostasis, folding and assembly processes of viral proteins, and reduces the replication capacity of viruses. Pochonin D reduces the infiltration of inflammatory cells, decreases the secretion of inflammatory cytokines such as TNF-α and IL-1β, and alleviates inflammatory responses. Pochonin D is a promising candidate for research on human rhinovirus (HRV) infection and cancer.
    Pochonin D